The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Selinexor for multiple myeloma
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discussess the role of selinexor in the treatment of multiple myeloma. Selinexor is an oral first-in-class selective inhibitor of nuclear export (SINE) compound, which has been approved in combination with bortezomib and dexamethasone for previously treated myeloma, and is now being explored in combination with pomalidomide-dexamethasone in relapsed/refractory myeloma. Dr Cerchione describes selinexor’s mechanism of action and gives an overview of the latest data on selinexor in novel combinations. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
